

# Francesca Romana Ponziani

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/5231409/francesca-romana-ponziani-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

91  
papers

2,443  
citations

28  
h-index

47  
g-index

102  
ext. papers

3,252  
ext. citations

4.3  
avg, IF

5.04  
L-index

#	Paper	IF	Citations
91	Risk factors for portal vein thrombosis or venous thromboembolism in a large cohort of hospitalized cirrhotic patients.. <i>Internal and Emergency Medicine</i> , <b>2022</b> , 1	3.7	0
90	Optimizing systemic therapy for advanced hepatocellular carcinoma: the key role of liver function.. <i>Digestive and Liver Disease</i> , <b>2022</b> ,	3.3	4
89	Viral hepatitis and hepatocellular carcinoma: From molecular pathways to the role of clinical surveillance and antiviral treatment. <i>World Journal of Gastroenterology</i> , <b>2022</b> , 28, 2251-2281	5.6	2
88	COVID-19 as a trigger of irritable bowel syndrome: A review of potential mechanisms. <i>World Journal of Gastroenterology</i> , <b>2021</b> , 27, 7433-7445	5.6	7
87	Improved gut microbiota features after the resolution of SARS-CoV-2 infection. <i>Gut Pathogens</i> , <b>2021</b> , 13, 62	5.4	1
86	Prognostic value of skeletal muscle mass during tyrosine kinase inhibitor (TKI) therapy in cancer patients: a systematic review and meta-analysis. <i>Internal and Emergency Medicine</i> , <b>2021</b> , 16, 1341-1356	3.7	3
85	Advances in pharmacotherapeutics for hepatocellular carcinoma. <i>Expert Opinion on Pharmacotherapy</i> , <b>2021</b> , 22, 1343-1354	4	2
84	Characterization of the gut-liver-muscle axis in cirrhotic patients with sarcopenia. <i>Liver International</i> , <b>2021</b> , 41, 1320-1334	7.9	9
83	Correlation Between Liver Function Tests Abnormalities and Interleukin-6 Serum Levels in Patients With SARS-CoV-2 Infection. <i>Gastroenterology</i> , <b>2021</b> , 160, 1891-1893	13.3	4
82	Low seroprevalence of SARS-CoV-2 antibodies in cirrhotic patients. <i>Digestive and Liver Disease</i> , <b>2021</b> , 53, 541-544	3.3	
81	Fecal Microbiota Transplantation in Patients with HBV Infection or Other Chronic Liver Diseases: Update on Current Knowledge and Future Perspectives. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	1
80	Italian association for the study of the liver position statement on SARS-CoV2 vaccination. <i>Digestive and Liver Disease</i> , <b>2021</b> , 53, 677-681	3.3	7
79	Management of liver disease in Italy after one year of the SARS-CoV-2 pandemic: A web-based survey. <i>Liver International</i> , <b>2021</b> , 41, 2228-2232	7.9	4
78	Missed linkage to care for patients who screened positive for Hepatitis C in a tertiary care centre: Results of the Telepass project. <i>Journal of Viral Hepatitis</i> , <b>2021</b> , 28, 651-656	3.4	3
77	Bariatric Surgery and Liver Disease: General Considerations and Role of the Gut-Liver Axis. <i>Nutrients</i> , <b>2021</b> , 13,	6.7	3
76	Risk of burnout and stress in physicians working in a COVID team: A longitudinal survey. <i>International Journal of Clinical Practice</i> , <b>2021</b> , 75, e14755	2.9	5
75	Letter to the Editor: Restructuring the Gut Microbiota of Patients with Cirrhosis After HCV Eradication: A Matter of Time?. <i>Hepatology</i> , <b>2021</b> , 74, 1718	11.2	1

74	Clinical update on the efficacy of anti-SARS-CoV-2 mRNA vaccines in patients on the waiting list for liver transplantation and in liver transplant recipients. <i>Digestive and Liver Disease</i> , <b>2021</b> , 53, 1232-1234	3.3	1
73	Intestinal Barrier in Human Health and Disease. <i>International Journal of Environmental Research and Public Health</i> , <b>2021</b> , 18,	4.6	17
72	Esophageal microbiome signature in patients with Barrett's esophagus and esophageal adenocarcinoma. <i>PLoS ONE</i> , <b>2020</b> , 15, e0231789	3.7	28
71	Effect of liver transplantation on intestinal permeability and correlation with infection episodes. <i>PLoS ONE</i> , <b>2020</b> , 15, e0235359	3.7	1
70	Liver involvement is not associated with mortality: results from a large cohort of SARS-CoV-2-positive patients. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 52, 1060-1068	6.1	34
69	Contrast-Enhanced Ultrasound in the Short-Term Evaluation of Hepatocellular Carcinoma after Locoregional Treatment. <i>Digestive Diseases</i> , <b>2020</b> , 38, 522-533	3.2	5
68	Gut microbiota compositional and functional fingerprint in patients with alcohol use disorder and alcohol-associated liver disease. <i>Liver International</i> , <b>2020</b> , 40, 878-888	7.9	32
67	NAFLD or comorbidities, that is the question. <i>Journal of Hepatology</i> , <b>2020</b> , 73, 723	13.4	1
66	Skeletal Muscle Loss during Multikinase Inhibitors Therapy: Molecular Pathways, Clinical Implications, and Nutritional Challenges. <i>Nutrients</i> , <b>2020</b> , 12,	6.7	6
65	Letter: prevalence and patterns of gastrointestinal symptoms in a large Western cohort of patients with COVID-19. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 52, 902-903	6.1	5
64	Gut Microbiota during Dietary Restrictions: New Insights in Non-Communicable Diseases. <i>Microorganisms</i> , <b>2020</b> , 8,	4.9	11
63	Assessing the impact of COVID-19 on the management of patients with liver diseases: A national survey by the Italian association for the study of the Liver. <i>Digestive and Liver Disease</i> , <b>2020</b> , 52, 937-941	3.3	22
62	Letter: liver involvement and mortality in COVID-19 patients - authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 52, 1264-1265	6.1	3
61	Diagnostic and therapeutic potential of the gut microbiota in patients with early hepatocellular carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , <b>2019</b> , 11, 1758835919848184	5.4	24
60	Interventional oncology treatments for unresectable early stage HCC in patients with a high risk for intraprocedural bleeding: Is a single-step combined therapy safe and feasible?. <i>European Journal of Radiology</i> , <b>2019</b> , 114, 32-37	4.7	7
59	Letter: improvement of clinical outcomes by metformin in metabolic liver disease-a microbiota-dependent mechanism?. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 50, 474	6.1	
58	Overview of Immune Checkpoint Inhibitors Therapy for Hepatocellular Carcinoma, and The ITA.LI.CA Cohort Derived Estimate of Amenability Rate to Immune Checkpoint Inhibitors in Clinical Practice. <i>Cancers</i> , <b>2019</b> , 11,	6.6	25
57	Minimal Hepatic Encephalopathy is Associated with Increased Cerebral Vascular Resistance. A Transcranial Doppler Ultrasound Study. <i>Scientific Reports</i> , <b>2019</b> , 9, 15373	4.9	3

56	Treatment of hepatocellular carcinoma in patients with portal vein tumor thrombosis: Beyond the known frontiers. <i>World Journal of Gastroenterology</i> , <b>2019</b> , 25, 4360-4382	5.6	43
55	Portal vein thrombosis in cirrhosis: Why a well-known complication is still matter of debate. <i>World Journal of Gastroenterology</i> , <b>2019</b> , 25, 4437-4451	5.6	28
54	Intestinal permeability in the pathogenesis of liver damage: From non-alcoholic fatty liver disease to liver transplantation. <i>World Journal of Gastroenterology</i> , <b>2019</b> , 25, 4814-4834	5.6	45
53	Gut Microbial, Inflammatory and Metabolic Signatures in Older People with Physical Frailty and Sarcopenia: Results from the BIOSPHERE Study. <i>Nutrients</i> , <b>2019</b> , 12,	6.7	43
52	Hepatic encephalopathy 2018: A clinical practice guideline by the Italian Association for the Study of the Liver (AISF). <i>Digestive and Liver Disease</i> , <b>2019</b> , 51, 190-205	3.3	36
51	Contrast-enhanced ultrasound patterns of hepatocellular adenoma: an Italian multicenter experience. <i>Journal of Ultrasound</i> , <b>2019</b> , 22, 157-165	3.4	8
50	Congenital extrahepatic portosystemic shunt: description of four cases and review of the literature. <i>Journal of Ultrasound</i> , <b>2019</b> , 22, 349-358	3.4	6
49	Hepatocellular Carcinoma Is Associated With Gut Microbiota Profile and Inflammation in Nonalcoholic Fatty Liver Disease. <i>Hepatology</i> , <b>2019</b> , 69, 107-120	11.2	230
48	Low molecular weight heparin as cause of liver injury: case report and literature review. <i>European Review for Medical and Pharmacological Sciences</i> , <b>2019</b> , 23, 7649-7654	2.9	3
47	Treatment of early stage chronic hepatitis C virus infection. <i>Expert Review of Clinical Pharmacology</i> , <b>2018</b> , 11, 519-524	3.8	4
46	Lack of reduction in serum alpha-fetoprotein during treatment with direct antiviral agents predicts hepatocellular carcinoma development in a large cohort of patients with hepatitis C virus-related cirrhosis. <i>Journal of Viral Hepatitis</i> , <b>2018</b> , 25, 1493-1500	3.4	3
45	Recurrence of hepatocellular carcinoma after direct acting antiviral treatment for hepatitis C virus infection: Literature review and risk analysis. <i>Digestive and Liver Disease</i> , <b>2018</b> , 50, 1105-1114	3.3	26
44	Sarcopenia in Patients with Advanced Liver Disease. <i>Current Protein and Peptide Science</i> , <b>2018</b> , 19, 681-698	1.8	21
43	Bile Collection Detected With BrIDA Scintigraphy in a Patient With Hepatocellular Carcinoma. <i>Clinical Nuclear Medicine</i> , <b>2018</b> , 43, 823-824	1.7	
42	Regorafenib: a promising treatment for hepatocellular carcinoma. <i>Expert Opinion on Pharmacotherapy</i> , <b>2018</b> , 19, 1941-1948	4	12
41	Influence of hepatitis C virus eradication with direct-acting antivirals on the gut microbiota in patients with cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 48, 1301-1311	6.1	36
40	Bacterial translocation in patients with liver cirrhosis: physiology, clinical consequences, and practical implications. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2018</b> , 12, 641-656	4.2	51
39	Portal vein thrombosis occurrence in a cirrhotic patient during treatment with rivaroxaban. <i>Liver International</i> , <b>2017</b> , 37, 1251	7.9	5

38	Effectiveness of Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir in Hemodialysis Patients With Hepatitis C Virus Infection and Advanced Liver Fibrosis: Case Reports. <i>American Journal of Kidney Diseases</i> , <b>2017</b> , 70, 297-300	7.4	12
37	Eubiotic properties of rifaximin: Disruption of the traditional concepts in gut microbiota modulation. <i>World Journal of Gastroenterology</i> , <b>2017</b> , 23, 4491-4499	5.6	74
36	Low risk of hepatitis B virus reactivation in patients with resolved infection and chronic myeloid leukemia treated with tyrosine kinase inhibitors. <i>Leukemia and Lymphoma</i> , <b>2017</b> , 58, 993-995	1.9	7
35	Thrombosis after liver transplantation for hepatocellular carcinoma. <i>PLoS ONE</i> , <b>2017</b> , 12, e0186699	3.7	6
34	Subclinical atherosclerosis is linked to small intestinal bacterial overgrowth vitamin K2-dependent mechanisms. <i>World Journal of Gastroenterology</i> , <b>2017</b> , 23, 1241-1249	5.6	22
33	Reverse time-dependent effect of alphafetoprotein and disease control on survival of patients with Barcelona Clinic Liver Cancer stage C hepatocellular carcinoma. <i>World Journal of Hepatology</i> , <b>2017</b> , 9, 1322-1331	3.4	2
32	Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis C. <i>World Journal of Hepatology</i> , <b>2017</b> , 9, 352-367	3.4	37
31	How to modulate gut microbiota: diet, preprobiotics or antibiotics?. <i>Minerva Gastroenterology</i> , <b>2017</b> , 63, 411-419	3	
30	Reply to Nezic. <i>European Journal of Cardio-thoracic Surgery</i> , <b>2016</b> , 49, 1021-2	3	
29	Diagnosis and treatment of small intestinal bacterial overgrowth. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2016</b> , 10, 215-27	4.2	34
28	Inducing tolerability of adverse events increases sorafenib exposure and optimizes patient's outcome in advanced hepatocellular carcinoma. <i>Liver International</i> , <b>2016</b> , 36, 1033-42	7.9	23
27	The Role of Antibiotics in Gut Microbiota Modulation: The Eubiotic Effects of Rifaximin. <i>Digestive Diseases</i> , <b>2016</b> , 34, 269-78	3.2	72
26	Rifaximin for the treatment of irritable bowel syndrome - a drug safety evaluation. <i>Expert Opinion on Drug Safety</i> , <b>2016</b> , 15, 983-91	4.1	13
25	Radial Artery as a Coronary Artery Bypass Conduit: 20-Year Results. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 68, 603-610	15.1	55
24	Physiology and pathophysiology of liver lipid metabolism. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2015</b> , 9, 1055-67	4.2	50
23	Morphological and functional consequences of transradial coronary angiography on the radial artery: implications for its use as a bypass conduit. <i>European Journal of Cardio-thoracic Surgery</i> , <b>2015</b> , 48, 370-4	3	26
22	Recipient female gender is a risk factor for graft loss after liver transplantation for chronic hepatitis C: Evidence from the prospective Liver Match cohort. <i>Digestive and Liver Disease</i> , <b>2015</b> , 47, 689-94	3.3	10
21	Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications. <i>World Journal of Gastroenterology</i> , <b>2015</b> , 21, 12322-33	5.6	47

20	Portal vein thrombosis and liver transplantation: implications for waiting list period, surgical approach, early and late follow-up. <i>Transplantation Reviews</i> , <b>2014</b> , 28, 92-101	3.3	47
19	Long-term maintenance of sustained virological response in liver transplant recipients treated for recurrent hepatitis C. <i>Digestive and Liver Disease</i> , <b>2014</b> , 46, 440-5	3.3	3
18	Liver transplantation in alcoholic patients: impact of an alcohol addiction unit within a liver transplant center. <i>Alcoholism: Clinical and Experimental Research</i> , <b>2013</b> , 37, 1601-8	3.7	115
17	Early prediction of response to sorafenib in patients with advanced hepatocellular carcinoma: the role of dynamic contrast enhanced ultrasound. <i>Journal of Hepatology</i> , <b>2013</b> , 59, 1014-21	13.4	57
16	Treatment of genotype-1 hepatitis C recurrence after liver transplant improves survival in both sustained responders and relapsers. <i>Transplant International</i> , <b>2013</b> , 26, 281-9	3	7
15	Gut microbiota and metabolic syndrome. <i>Internal and Emergency Medicine</i> , <b>2013</b> , 8 Suppl 1, S11-5	3.7	55
14	Use and indications of cholestyramine and bile acid sequestrants. <i>Internal and Emergency Medicine</i> , <b>2013</b> , 8, 205-10	3.7	54
13	Diagnosis of bowel diseases: the role of imaging and ultrasonography. <i>World Journal of Gastroenterology</i> , <b>2013</b> , 19, 2144-53	5.6	17
12	Treatment of hepatitis C in compensated cirrhotic patients is equally effective before and after liver transplantation. <i>World Journal of Gastroenterology</i> , <b>2013</b> , 19, 3255-62	5.6	5
11	Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation. <i>World Journal of Gastroenterology</i> , <b>2013</b> , 19, 7515-30	5.6	80
10	Treatment of hepatitis C recurrence is less successful in female than in male liver transplant recipients. <i>Transplant International</i> , <b>2012</b> , 25, 448-54	3	10
9	What we should know about portal vein thrombosis in cirrhotic patients: a changing perspective. <i>World Journal of Gastroenterology</i> , <b>2012</b> , 18, 5014-20	5.6	32
8	Treatment of recurrent genotype 4 hepatitis C after liver transplantation: early virological response is predictive of sustained virological response. An AISF RECOLT-C group study. <i>Annals of Hepatology</i> , <b>2012</b> , 11, 338-42	3.1	3
7	Anticoagulants in cirrhotic patients: controversies and certainties in PVT management. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , <b>2011</b> , 9, 183-9	1.9	5
6	Management of hepatitis C virus infection recurrence after liver transplantation: an overview. <i>Transplantation Proceedings</i> , <b>2011</b> , 43, 291-5	1.1	15
5	The metabolic and toxicological considerations for mTOR inhibitors in the treatment of hepatocarcinoma. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2011</b> , 7, 1535-46	5.5	5
4	Portal vein thrombosis: insight into physiopathology, diagnosis, and treatment. <i>World Journal of Gastroenterology</i> , <b>2010</b> , 16, 143-55	5.6	179
3	Is there a role for anticoagulants in portal vein thrombosis management in cirrhotic patients?. <i>Expert Opinion on Pharmacotherapy</i> , <b>2010</b> , 11, 1479-87	4	12

- |   |   |      |     |
|---|---|------|-----|
| 2 | Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development. <i>Journal of Hepatology</i> , <b>2009</b> , 51, 682-9 | 13.4 | 321 |
| 1 | Viral cirrhosis: an overview of haemostatic alterations and clinical consequences. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , <b>2009</b> , 1, e2009033             | 3.2  | 3   |